Tenax Therapeutics, Inc. (TENX): who owns it and who trades it
As of Nov 16, 2026, TENX insiders reported 27 purchases worth $6.6M in the last 12 months. The largest buyer was Daniel Schneeberger (10% owner), with $3.2M. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Tenax Therapeutics
From the latest filingsOverall: more buying than selling. Funds, insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns TENX
111 funds and institutions reported TENX shares worth $442M at the end of Q2 2026, about 67% of the company. The largest holder is FMR LLC (Fidelity) with 8.7%.
Funds and institutions (13F) 67%Everyone else 33%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 3.94M | 8.66% | $57.4M | +1122% |
| Vivo Capital, LLC | 2.50M | 5.49% | $36.4M | +1100% |
| BlackRock, Inc. | 1.73M | 3.79% | $25.1M | +10078% |
| Perceptive Advisors LLC | 1.70M | 3.73% | $24.7M | +17% |
| Vanguard Capital Management LLC | 1.15M | 2.52% | $16.7M | +335% |
| Millennium Management LLC | 876,230 | 1.92% | $12.7M | +64% |
| Ikarian Capital, LLC | 787,600 | 1.73% | $11.5M | -23% |
| Candriam S.C.A. | 749,588 | 1.65% | $10.9M | New |
| Citadel Advisors LLC | 728,561 | 1.60% | $10.6M | +378% |
| Rtw Investments, LP | 696,570 | 1.53% | $10.1M | +88% |
| Stonepine Capital Management, LLC | 660,000 | 1.45% | $9.6M | -32% |
| Geode Capital Management, LLC | 639,537 | 1.40% | $9.3M | +825% |
| T. Rowe Price Associates | 607,660 | 1.33% | $8.8M | -79% |
| Marshall Wace, LLP | 585,578 | 1.29% | $8.5M | +66% |
| Braidwell LP | 584,412 | 1.28% | $8.5M | New |
| Point72 Asset Management, L.P. | 556,761 | 1.22% | $8.1M | +4% |
| Velan Capital Investment Management LP | 549,985 | 1.21% | $8M | -6% |
| Adage Capital Partners Gp, L.l.c. | 540,126 | 1.19% | $7.9M | No change |
| Woodline Partners LP | 531,254 | 1.17% | $7.7M | +64% |
| State Street Corp | 510,814 | 1.12% | $7.4M | +1662% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, TENX insiders reported $6.6M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 21, 2026 | ADAR1 Capital Management, LLC +1 | 10% owner | Purchase | 331,979 | $1.66 | $551K | Form 4 |
| Oct 20, 2026 | ADAR1 Capital Management, LLC +1 | 10% owner | Purchase | 254,342 | $1.60 | $406K | Form 4 |
| Oct 19, 2026 | ADAR1 Capital Management, LLC +1 | 10% owner | Purchase | 336,528 | $1.51 | $507K | Form 4 |
| Sep 16, 2026 | Declan Doogan | Director | Purchase | 53,000 | $1.92 | $102K | Form 4 |
| Sep 15, 2026 | Christopher Thomas Giordano | CEO | Purchase | 4,850 | $1.82 | $8.8K | Form 4 |
| Sep 11, 2026 | Christopher Thomas Giordano | CEO | Purchase | 6,000 | $1.88 | $11.3K | Form 4 |
| Sep 11, 2026 | Thomas R Staab II | CFO | Purchase | 5,675 | $1.94 | $11K | Form 4 |
| Sep 3, 2026 | ADAR1 Capital Management, LLC +1 | 10% owner | Purchase | 900,000 | $1.78 | $1.6M | Form 4 |
| Sep 2, 2026 | Daniel Schneeberger +1 | 10% owner | Purchase | 187,704 | $1.80 | $338K | Form 4 |
| Sep 1, 2026 | Daniel Schneeberger +1 | 10% owner | Purchase | 179,058 | $1.80 | $322K | Form 4 |
| Aug 31, 2026 | Daniel Schneeberger +1 | 10% owner | Purchase | 403,571 | $1.79 | $722K | Form 4 |
| Aug 24, 2026 | Daniel Schneeberger +1 | 10% owner | Purchase | 107,374 | $1.75 | $188K | Form 4 |
| Aug 21, 2026 | Daniel Schneeberger +1 | 10% owner | Purchase | 716,369 | $1.77 | $1.3M | Form 4 |
| Aug 20, 2026 | Daniel Schneeberger +1 | 10% owner | Purchase | 202,124 | $1.78 | $360K | Form 4 |
| Dec 9, 2025 | Stuart Rich | Director | Purchase | 2,500 | $10.22 | $25.6K | Form 4 |
| Dec 8, 2025 | Stuart Rich | Director | Purchase | 2,500 | $10.10 | $25.2K | Form 4 |
| Dec 4, 2025 | Stuart Rich | Director | Purchase | 2,500 | $9.20 | $23K | Form 4 |
| Dec 3, 2025 | Stuart Rich | Director | Purchase | 1,500 | $9.08 | $13.6K | Form 4 |
| Dec 2, 2025 | Stuart Rich | Director | Purchase | 1,000 | $9.01 | $9K | Form 4 |
| Nov 20, 2025 | Christopher Thomas Giordano | CEO | Purchase | 538 | $7.59 | $4.1K | Form 4 |
| Nov 19, 2025 | Christopher Thomas Giordano | CEO | Purchase | 455 | $7.51 | $3.4K | Form 4 |
| Nov 18, 2025 | Christopher Thomas Giordano | CEO | Purchase | 1,612 | $7.75 | $12.5K | Form 4 |
| Nov 18, 2025 | June Sherie Almenoff | Director | Purchase | 1,900 | $7.52 | $14.3K | Form 4 |
| Nov 17, 2025 | June Sherie Almenoff | Director | Purchase | 93 | $7.15 | $665 | Form 4 |
| Nov 17, 2025 | Thomas Mcgauley | CFO | Purchase | 5,000 | $7.23 | $36.1K | Form 4 |
| Nov 17, 2025 | Thomas Mcgauley | CFO | Purchase | 1,000 | $7.35 | $7.3K | Form 4 |
| Nov 17, 2025 | Thomas Mcgauley | CFO | Purchase | 2,000 | $7.34 | $14.7K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Daniel Schneeberger | 10% owner | $3.2M | – | Sep 2, 2026 |
| ADAR1 Capital Management, LLC | 10% owner | $3.1M | – | Oct 21, 2026 |
| Declan Doogan | Director | $102K | – | Sep 16, 2026 |
| Stuart Rich | Chief Medical Officer, Director | $96.4K | – | Dec 9, 2025 |
| Thomas Mcgauley | Interim CFO | $58.2K | – | Nov 17, 2025 |
| Christopher Thomas Giordano | CEO, Director | $40.1K | – | Sep 15, 2026 |
| June Sherie Almenoff | Director | $15K | – | Nov 18, 2025 |
| Thomas R Staab II | Chief Financial Officer | $11K | – | Sep 11, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
TENX short interest
High short interest. 15.5% of TENX shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 650%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 5.82M TENX shares were sold short, 15.5% of the shares outstanding, down 19.5% from the report before. At the average daily volume of 1.83M shares, buying them all back would take about 3.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 5.82M | 15.54% | -20% | 1.83M | 3.2 |
| Oct 15, 2026 | 7.23M | 19.32% | +1% | 2.25M | 3.2 |
| Sep 30, 2026 | 7.18M | 19.19% | +30% | 3.06M | 2.4 |
| Sep 15, 2026 | 5.50M | 14.71% | -41% | 5.35M | 1.0 |
| Aug 31, 2026 | 9.28M | 24.79% | +69% | 8.25M | 1.1 |
| Aug 14, 2026 | 5.47M | 14.63% | +114% | 13.36M | 1.0 |
| Jul 31, 2026 | 2.56M | 6.83% | +25% | 1.37M | 1.9 |
| Jul 15, 2026 | 2.05M | 11.90% | +14% | 1.49M | 1.4 |
| Jun 30, 2026 | 1.79M | 10.40% | +133% | 1.51M | 1.2 |
| Jun 15, 2026 | 767,532 | 4.46% | -3% | 941,212 | 1.0 |
| May 29, 2026 | 792,041 | 4.61% | +2% | 443,319 | 1.8 |
| May 15, 2026 | 775,851 | 4.51% | +6% | 693,464 | 1.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Tenax Therapeutics company events
Tenax Therapeutics filed 14 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 8, 2026AnnouncementAs previously announced, Tenax Therapeutics, Inc. is enriching its LEVEL-2 clinical trial based on key learnings from its recently completed Phase 3 LEVEL trial of TNX-103 in PH-HFpEF. The Company intends to amend LEVEL-2 enrollment criteria, as set forth in the attached Investor Presentation. Filing
- Sep 9, 2026AnnouncementShared information with investors. Filing
- Aug 10, 2026AnnouncementTenax Therapeutics, Inc. issued a press release announcing topline results from its Phase 3 LEVEL clinical trial of TNX-103 in patients with PH-HFpEF. As announced, the Company intends to host a conference call and live webcast at 8:00 a.m., ET on August 10, 2026 related to those results. Filing
- Jul 31, 2026ResultsReleased financial results. Filing
- Jul 2, 2026AnnouncementTenax Therapeutics, Inc. issued a press release announcing that it will present results from its Phase 3 LEVEL clinical trial in a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026. Filing
- Jun 30, 2026AgreementSupply Agreement As previously disclosed, pursuant to the License Agreement (as defined below) between Tenax Therapeutics, Inc. and Orion Corporation, a Finnish corporation, Orion has the right to be the Company’s primary supplier of orally administered levosimendan product for development purposes… Filing
- Jun 29, 2026LeadershipThe Board of Directors of Tenax Therapeutics, Inc., upon the recommendation of the Compensation Committee of the Board, approved amendments to the employment agreements of Christopher Giordano, Thomas Staab, and Stuart Rich. Filing
- Jun 4, 2026VoteReported shareholder vote results. Filing
- May 12, 2026ResultsReleased financial results. Filing
- Apr 22, 2026LeadershipTenax Therapeutics, Inc. announced the appointment of Thomas R. Staab, II as Chief Financial Officer of the Company effective May 11, 2026. Filing
- Mar 10, 2026ResultsReleased financial results. Filing
- Jan 9, 2026LeadershipThe Company and its Chief Medical Officer, Dr. Stuart Rich, entered into a second amendment to Dr. Rich’s Executive Employment Agreement dated January 15, 2021, as amended on June 12, 2024. Filing
- Dec 17, 2025AnnouncementTenax Therapeutics, Inc. issued a press release announcing that the prespecified Blinded Sample Size Re-estimation (BSSR) of LEVEL, an ongoing, registrational Phase 3 clinical trial evaluating TNX-103 (oral levosimendan) in patients with pulmonary hypertension in heart failure with preserved… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Tenax Therapeutics financials
Famous investors that hold TENX
1 of the 50 well-known investors we track reported holding TENX in their latest 13F filing. The largest position is Israel Englander's, worth $2.6M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 1.36M | $2.6M | 0.0% | +56% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 20 filings named TENX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Sirenia Capital Management LP | 13G | 5.4% |
| Nov 16, 2026 | Sirenia Capital Management LP | 13G | 5.4% |
| Nov 16, 2026 | ADAR1 Capital Management, LLC | 13G/A | 16.4% |
| Nov 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 8.2% |
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 0.0% |
| Nov 16, 2026 | RTW Investments, LP | 13G/A | 0.0% |
| Nov 16, 2026 | Vestal Point Capital, LP | 13G/A | 0.0% |
| Nov 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 8.2% |
| Nov 16, 2026 | ADAR1 Capital Management, LLC | 13G/A | 16.4% |
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 0.0% |
| Nov 16, 2026 | RTW Investments, LP | 13G/A | 0.0% |
| Nov 16, 2026 | Vestal Point Capital, LP | 13G/A | 0.0% |
| Nov 12, 2026 | Adage Capital Management, L.P. | 13G/A | 2.3% |
| Nov 12, 2026 | Adage Capital Management, L.P. | 13G/A | 2.3% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 7.5% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 7.5% |
| Oct 15, 2026 | Millennium Management LLC | 13G/A | 3.6% |
| Oct 15, 2026 | Millennium Management LLC | 13G/A | 3.6% |
| Oct 13, 2026 | Sphera Funds Management Ltd. | 13G/A | 7.1% |
| Oct 13, 2026 | Sphera Funds Management Ltd. | 13G/A | 7.1% |
Questions about Tenax Therapeutics, Inc. (TENX) stock
Who owns the most TENX stock?
The largest reported owner of Tenax Therapeutics, Inc. (TENX) is FMR LLC (Fidelity), with 8.7% of the company. In total, 111 funds and institutions reported holding TENX at the end of Q2 2026, together about 67% of the shares. See the largest owners.
Are TENX insiders buying or selling?
In the last 12 months, TENX insiders reported 27 open-market purchases worth $6.6M and no sales. The latest trade was on Oct 21, 2026. See every trade.
What is the short interest in TENX?
As of Oct 30, 2026, 5.82M TENX shares were sold short, 15.5% of the shares outstanding, down 19.5% from the report before. At the average daily volume of 1.83M shares, buying them all back would take about 3.2 trading days (days to cover). See the history.
Which famous investors hold TENX?
1 of the 50 well-known investors we track reported TENX in their latest 13F filing, including Israel Englander. The largest position is worth $2.6M. See all holders.
Executive pay
Tenax Therapeutics's chief executive was paid a total of $8.1M for the year ended Dec 31, 2025, up 9% from $7.4M the year before. In the last 12 months, Tenax Therapeutics's executives and directors bought $322K of stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.